Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is InterMedical Care and Lab Hospital PCL EV-to-EBITDA?
InterMedical Care and Lab Hospital PCLBKK:IMH -8.37%65 EV-to-EBITDA is 30.28 as of Aug. 29, 2026, which is 75% above its 10-year median of 17.29. GuruFocus rates BKK:IMH with a GF Score™ of 65/100 and a GF Value™ of ฿4.17 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 517 Healthcare Providers & Services companies, InterMedical Care and Lab Hospital PCL ranks worse than 85.69% on this metric.
BKK:IMH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -185.82 Med: 17.29 Max: 588.86
Current: 30.28
During the past 10 years, the highest EV-to-EBITDA of InterMedical Care and Lab Hospital PCL was 588.86. The lowest was -185.82. And the median was 17.29.
BKK:IMH's EV-to-EBITDA is ranked worse than 85.69% of 517
companies
in the Healthcare Providers & Services industry
Industry Median: 10.49
vs BKK:IMH: 30.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
InterMedical Care and Lab Hospital PCL (BKK:IMH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
InterMedical Care and Lab Hospital PCL's PE Ratio (TTM) for today is calculated as:
InterMedical Care and Lab Hospital PCL's share price for today is ฿3.72.
InterMedical Care and Lab Hospital PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿-0.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InterMedical Care and Lab Hospital PCL EV-to-EBITDA Chart
InterMedical Care and Lab Hospital PCL Annual Data
For the Medical Care Facilities subindustry, InterMedical Care and Lab Hospital PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InterMedical Care and Lab Hospital PCL EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, InterMedical Care and Lab Hospital PCL's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where InterMedical Care and Lab Hospital PCL's EV-to-EBITDA falls into.
InterMedical Care and Lab Hospital PCL's current Enterprise Value is ฿1,979.9 Mil.
InterMedical Care and Lab Hospital PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿65.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InterMedical Care and Lab Hospital PCL (BKK:IMH) has a EV-to-EBITDA of 30.28 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on InterMedical Care and Lab Hospital PCL. This is 75% above median its historical median of 17.29. According to the industry distribution chart, InterMedical Care and Lab Hospital PCL ranks #443 out of 517 companies in the Healthcare Providers & Services industry, placing it in the top 85.7%.
Is InterMedical Care and Lab Hospital PCL's EV-to-EBITDA too high?
InterMedical Care and Lab Hospital PCL's current EV-to-EBITDA of 30.28 is 75% above median its 10-year median of 17.29. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.49. InterMedical Care and Lab Hospital PCL's value of 30.28 is 188.7% above this industry median. Based on the distribution chart, InterMedical Care and Lab Hospital PCL ranks #443 out of 517 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, InterMedical Care and Lab Hospital PCL has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does InterMedical Care and Lab Hospital PCL's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, InterMedical Care and Lab Hospital PCL ranks #443 out of 517 companies for EV-to-EBITDA. This places InterMedical Care and Lab Hospital PCL in the lower half of its industry. The industry median EV-to-EBITDA is 10.49. InterMedical Care and Lab Hospital PCL's value of 30.28 is 188.7% above this benchmark. While the company's 10-year median is 17.29 vs. the industry median of 10.49, InterMedical Care and Lab Hospital PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.49, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InterMedical Care and Lab Hospital PCL's current EV-to-EBITDA of 30.28 is 188.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on InterMedical Care and Lab Hospital PCL. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InterMedical Care and Lab Hospital PCL's current EV-to-EBITDA is 30.28, which is 75% above median its own 10-year median of 17.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InterMedical Care and Lab Hospital PCL stock overvalued right now?
Based on GuruFocus' analysis, InterMedical Care and Lab Hospital PCL (BKK:IMH) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿4.17, compared to a current price of ฿3.72 — trading 10.8% below its estimated fair value. The current EV-to-EBITDA is 30.28, which is 75% above median its 10-year median of 17.29 and 188.7% above the Healthcare Providers & Services industry median of 10.49. InterMedical Care and Lab Hospital PCL's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For InterMedical Care and Lab Hospital PCL (BKK:IMH), the current EV-to-EBITDA is 30.28 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InterMedical Care and Lab Hospital PCL (BKK:IMH) Overvalued in 2026?
Based on GuruFocus' analysis, InterMedical Care and Lab Hospital PCL stock appears to be undervalued.
The current stock price of ฿3.72 is trading 10.8% below its estimated GF Value™ of ฿4.17.
GuruFocus considers InterMedical Care and Lab Hospital PCL to be Modestly Undervalued.
Key valuation signals for BKK:IMH:
EV-to-EBITDA: 30.28 (75% above median its 10-year median of 17.29)
GF Value™: ฿4.17 vs. price of ฿3.72 (10.8% below fair value)
Industry Position: 188.7% above the Healthcare Providers & Services median (#443 of 517)
No single metric tells the full story. See the BKK:IMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InterMedical Care and Lab Hospital PCL is a company principally engaged in specialty medical hospitals, and occupational medicine. The business segments of the firm are Prachapat hospital, Occupational Medicine hospital and Environmental Analysis. Prachapat Hospital is engaged in rendering medical services to patients under government welfare schemes. Occupational Medicine Hospital is engaged in providing physical examination services. Majority of revenue is from Hospital Segment. Geographically, the company operates in Thailand.
65GF Score
Get the complete analysis for BKK:IMH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:IMH has been successfully added to your 
